SCHEMBL4412489

SCHEMBL4412489

Cc1ccn(-c2nc(O)c3[c]cccc3n2)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4406314 0.82
SCHEMBL8248762 0.78 MAPK1 (0.36)
SCHEMBL4404585 0.75
SCHEMBL4404597 0.75 MAPT (0.41)
SCHEMBL4413940 0.71 ADORA2A (0.37)
SCHEMBL4404584 0.71 HSD17B10 (0.45)
SCHEMBL4408162 0.64 GBA1 (0.37)
SCHEMBL9863892 0.63 ACHE (0.30)
SCHEMBL8703598 0.63 NQO2 (0.35)
SCHEMBL4406848 0.63 SMN1; SMN2 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325889-A1 HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR CAMPBELL DAVID ALAN 2009-12-31 US claimed
EP-1915382-A2 HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR Phenomix Corporation (US) 2008-04-30 EP claimed
WO-2007016476-A2 HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR PHENOMIX CORPORATION (US) 2007-02-08 WO claimed
US-20090325889-A1 HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR CAMPBELL DAVID ALAN 2009-12-31 US disclosed